glp-1 long term weight loss agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis GLP-1 Medications Beyond Weight Loss

It found half (51 per cent) of employers said they cover the medications only for diabetes, down from 56 per cent last year and 66 per cent in 2024

Patients who implement structured maintenance strategies , including gradual tapering, exercise, dietary habits, and monitoring, retain more of their weight loss than those who stop abruptly

A further aspect is scalability

Key takeaways: First regulatory endorsement linking GLP-1 receptor agonists to MASH treatment Targets adults with non-cirrhotic MASH and moderateadvanced fibrosis Builds on GLP-1 success in obesity and type 2 diabetes Demonstrates histological improvement in liver inflammation and fibrosis Reinforces the role of metabolic pathways in chronic liver disease management This approval signals a shift toward disease-modifying therapies for MASH and highlights how metabolic drugs are reshaping hepatology across Europe